1 |
Pasricha PJ, Yates KP, Sarosiek I, et al. Aprepitant has mixed effects on nausea and reduces other symptoms in patients with gastroparesis and related disorders. Gastroenterology 2018;154:65-76.e11.
DOI
|
2 |
Parkman HP, Hasler WL, Fisher RS, American Gastroenterological Association. American Gastroenterological Association technical review on the diagnosis and treatment of gastroparesis. Gastroenterology 2004;127:1592-1622.
DOI
|
3 |
Stanghellini V, Tack J. Gastroparesis: separate entity or just a part of dyspepsia? Gut 2014;63:1972-1978.
DOI
|
4 |
Pasricha PJ, Yates KP, Nguyen L, et al. Outcomes and factors associated with reduced symptoms in patients with gastroparesis. Gastroenterology 2015;149:1762-1774.e4.
DOI
|
5 |
Hornby PJ. Central neurocircuitry associated with emesis. Am J Med 2001;111 Suppl 8A:106S-112S.
DOI
|
6 |
Stapleton J, Wo JM. Current treatment of nausea and vomiting associated with gastroparesis: antiemetics, prokinetics, tricyclics. Gastrointest Endosc Clin N Am 2009;19:57-72, vi.
DOI
|
7 |
Acosta A, Camilleri M. Prokinetics in gastroparesis. Gastroenterol Clin North Am 2015;44:97-111.
DOI
|
8 |
Lacy BE, Parkman HP, Camilleri M. Chronic nausea and vomiting: evaluation and treatment. Am J Gastroenterol 2018;113:647-659.
DOI
|
9 |
Camilleri M, Parkman HP, Shafi MA, Abell TL, Gerson L, American College of Gastroenterology. Clinical guideline: management of gastroparesis. Am J Gastroenterol 2013;108:18-37; quiz 38.
DOI
|
10 |
Camilleri M. Novel diet, drugs, and gastric interventions for gastroparesis. Clin Gastroenterol Hepatol 2016;14:1072-1080.
DOI
|
11 |
Tack J, Camilleri M. New developments in the treatment of gastroparesis and functional dyspepsia. Curr Opin Pharmacol 2018;43:111-117.
DOI
|
12 |
Parkman HP, Carlson MR, Gonyer D. Metoclopramide nasal spray reduces symptoms of gastroparesis in women, but not men, with diabetes: results of a phase 2B randomized study. Clin Gastroenterol Hepatol 2015;13:1256-1263.e1.
DOI
|
13 |
Coulie B, Tack J, Peeters T, Janssens J. Involvement of two different pathways in the motor effects of erythromycin on the gastric antrum in humans. Gut 1998;43:395-400.
DOI
|
14 |
Larson JM, Tavakkoli A, Drane WE, Toskes PP, Moshiree B. Advantages of azithromycin over erythromycin in improving the gastric emptying half-time in adult patients with gastroparesis. J Neurogastroenterol Motil 2010;16:407-413.
DOI
|
15 |
Sanger GJ, Pasricha PJ. Investigational drug therapies for the treatment of gastroparesis. Expert Opin Investig Drugs 2017;26:331-342.
DOI
|
16 |
Carbone F, Rotondo A, Andrews CN, et al. 1077 a controlled cross-over trial shows benefit of prucalopride for symptom control and gastric emptying enhancement in idiopathic gastroparesis. Gastroenterology 2016;150:S213-S214.
|
17 |
Camilleri M, Acosta A. Emerging treatments in neurogastroenterology: relamorelin: a novel gastrocolokinetic synthetic ghrelin agonist. Neurogastroenterol Motil 2015;27:324-332.
DOI
|
18 |
Camilleri M, McCallum RW, Tack J, Spence SC, Gottesdiener K, Fiedorek FT. Efficacy and safety of relamorelin in diabetics with symptoms of gastroparesis: a randomized, placebo-controlled study. Gastroenterology 2017;153:1240-1250.e2.
DOI
|
19 |
Abell T, Lou J, Tabbaa M, Batista O, Malinowski S, Al-Juburi A. Gastric electrical stimulation for gastroparesis improves nutritional parameters at short, intermediate, and long-term follow-up. JPEN J Parenter Enteral Nutr 2003;27:277-281.
DOI
|
20 |
Rojas C, Raje M, Tsukamoto T, Slusher BS. Molecular mechanisms of 5-HT(3) and NK(1) receptor antagonists in prevention of emesis. Eur J Pharmacol 2014;722:26-37.
DOI
|
21 |
Yokoe T, Hayashida T, Nagayama A, et al. Effectiveness of antiemetic regimens for highly emetogenic chemotherapy-induced nausea and vomiting: a systematic review and network meta-analysis. Oncologist 2018 Oct 17. [Epub ahead of print]
|
22 |
Jacobse J, Mensink H, van der Stoep-Yap MYEC, Kollen WJW, Bresters D, Bredius RGM. Long-term aprepitant for nausea and vomiting associated with gastroparesis in hematopoietic stem cell transplantation. Bone Marrow Transplant 2018;53:1372-1374.
DOI
|
23 |
Singh PM, Borle A, Rewari V, et al. Aprepitant for postoperative nausea and vomiting: a systematic review and meta-analysis. Postgrad Med J 2016;92:87-98.
DOI
|
24 |
Fahler J, Wall GC, Leman BI. Gastroparesis-associated refractory nausea treated with aprepitant. Ann Pharmacother 2012;46:e38.
|
25 |
Fountoulakis N, Dunn J, Thomas S, Karalliedde J. Successful management of refractory diabetic gastroparesis with long-term aprepitant treatment. Diabet Med 2017;34:1483-1486.
DOI
|
26 |
Chong K, Dhatariya K. A case of severe, refractory diabetic gastroparesis managed by prolonged use of aprepitant. Nat Rev Endocrinol 2009;5:285-288.
DOI
|